Christian Martin Itin
Chief Executive Officer bij AUTOLUS THERAPEUTICS PLC
Vermogen: 7 M $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Matthias Alder | M | 59 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland.
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Autolus Holdings (UK) Ltd.
Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The private company is based in London, UK and was founded in 2018. | 14 jaar |
Martin Murphy | M | 55 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 10 jaar |
John Berriman | M | 76 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 17 jaar |
Martin Pulé | M | 51 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 10 jaar |
Allan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 14 jaar |
Kapil Dhingra | M | 64 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 14 jaar |
Joseph Anderson | M | 65 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 12 jaar |
Joost de Bruijn | M | 58 | 7 jaar | |
Cynthia Butitta | F | 70 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 6 jaar |
Sean E. Harper | M | 61 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 jaar |
David J. Scott | M | 71 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 jaar |
Linda Bain | F | 53 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 6 jaar |
Olivia Manser | F | - | 2 jaar | |
David Brochu | M | - | 5 jaar | |
Erwin Boos | M | 46 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Oliver Walker | M | 55 | 6 jaar | |
Timothy Nigel Carl Wells | M | 62 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Tan Li | F | 60 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Clemens A. van Blitterswijk | M | 67 | 7 jaar | |
Alexander Swan | M | - | 3 jaar | |
Alex Driggs | M | 48 | - | |
Alan Bradley | M | 64 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | - |
Timothy James Rink | M | 78 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Scott P. Bruder | M | 62 | 6 jaar | |
Simone Song | F | 59 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Brent Rice | M | 58 | 3 jaar | |
Douglas Fearon | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Volker Germaschewski | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Paul Kellam | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Julia Wilson | F | - | - | |
Dominic Michael Moreland | M | 59 |
Autolus Holdings (UK) Ltd.
Autolus Holdings (UK) Ltd. BiotechnologyHealth Technology Part of Autolus Therapeutics Plc, Autolus Holdings (UK) Ltd. is a holding British company that operates subsidiaries engaged in pharmaceutical research and development activities. The private company is based in London, UK and was founded in 2018. | - |
Veronica Hersberger | M | - | 1 jaar | |
Christopher Vann | M | 59 | 8 jaar | |
Miranda Neville | F | - | 6 jaar | |
Robert Dolski | M | 54 | 1 jaar | |
Elisabeth Leiderman | M | 47 | 1 jaar | |
Robert Azelby | M | 56 | - | |
Robert Iannone | M | 57 | 1 jaar | |
Leanna Caron | F | 56 | 8 jaar | |
Philippe Saudan | M | 57 | 8 jaar | |
Brian M. McNamee | M | 67 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 jaar |
Jasper Clube | M | 56 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Nigel Clark | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Robert Bradway | M | 61 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 jaar |
Glenn Alfons Friedrich | M | - |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Alf Gunnar Martin Nicklasson | M | 69 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | 7 jaar |
William Young | M | 79 | 3 jaar | |
Kevin Sharer | M | 76 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 jaar |
Florence Barrère de Groot | M | - | 7 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Harry Welten | M | 59 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 8 jaar |
Lucinda Crabtree | M | 45 | 3 jaar | |
Didier Cowling | M | 59 | 18 jaar | |
Carsten Reinhardt | M | 57 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | 4 jaar |
Jerry Christopher Benjamin | M | 83 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | 5 jaar |
Michael Carter | M | 86 |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany.
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 11 jaar |
Ivan Cohen-Tanugi | M | - | - | |
Jay Backstrom | M | 69 | 3 jaar | |
Edward Hodgkin | M | 61 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | 4 jaar |
Jonathan Peacock | M | 66 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Joseph Slattery | M | 59 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 5 jaar |
Gerhard Ries | M | 55 | 3 jaar | |
Peter Johann | M | 67 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Philipp Mueller | M | 71 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 10 jaar |
Jason M. Hannon | M | 52 | - | |
Giacomo di Nepi | M | 72 | 2 jaar | |
Michael Grau | M | 62 | 5 jaar | |
Jakob Schlapbach | M | 73 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 12 jaar |
John Johnson | M | 66 | 3 jaar | |
Pascal Longlade | M | 62 | - | |
Jason Schense | M | 52 | 17 jaar | |
Yamo Deniz | M | 60 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 1 jaar |
Ashley Hall | F | 52 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 2 jaar |
Malte Peters | M | 61 |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | 1 jaar |
Vijay Reddy Peddareddigari | M | 52 | 4 jaar | |
Neil Bell | M | 67 | 3 jaar | |
Adam Hacker | M | 55 | 3 jaar | |
Charlie Campion | M | - | 5 jaar | |
Nushmia Khokhar | M | - | - | |
Virginia Jamieson | M | 71 | 2 jaar | |
Ivor Royston | M | 79 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Frank-Jan van der Velden | M | 65 | 1 jaar | |
Kurt von Emster | M | 56 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | 3 jaar |
James Clayburn la Force | M | 95 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Ulrich Grau | M | 75 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 1 jaar |
Guy M. Gammon | M | - |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Robert E. Kiss | M | - |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Jens Hennecke | M | 56 |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | 5 jaar |
Jan C. Fagerberg | M | 62 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
Phillip Schneider | M | 68 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 1 jaar |
Christopher P. Schnittker | M | 55 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 1 jaar |
Donald A. Zelm | M | 68 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 2 jaar |
Donald L. Morton | M | - |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | - |
William LaRue | M | 73 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 5 jaar |
Jörg Neermann | M | 57 | 2 jaar | |
Patrick Baeuerle | M | 66 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 14 jaar |
Andrew Oakley | M | 62 | 4 jaar | |
David Hale | M | 75 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 12 jaar |
Otello Stampacchia | M | 55 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 4 jaar |
Mark Reisenauer | M | 58 |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | 4 jaar |
Edgar Braendle | M | - | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 47 | 47.00% |
Verenigde Staten | 30 | 30.00% |
Zwitserland | 26 | 26.00% |
Duitsland | 5 | 5.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Christian Martin Itin
- Persoonlijk netwerk